Article ID: 2026-0358
Background: Platelet-rich plasma (PRP) is a modality for chronic low back pain (LBP), despite its unknown clinical efficacy. This systematic review with meta-analysis analyzed PRP for LBP compared with other interventions categorized by target tissue.
Methods: Ovid MEDLINE, Cochrane, Embase, Scopus, and Web of Science were searched up to October 2024 for randomized controlled trials (RCTs) comparing PRP injections with control interventions, in accordance with PRISMA guidelines.
Results: Twenty RCTs were included. Results showed a time- and tissue-dependent trajectory, demonstrating a statistically significant advantage for PRP in pain reduction at the 3-month follow-up across both discogenic and chronic LBP etiologies. While early (1-month) and late (6-month) intervals exhibited high baseline heterogeneity, mixed-effects meta-regression demonstrated that control selection accounted for 84% to 100% of this variance, indicating that early therapeutic efficiency was an artifact. Conversely, functional disability outcomes measured via the Oswestry Disability Index, a more objective outcome assessment, remained statistically neutral at 4 months. PRP therapy demonstrated an excellent safety profile with only transient, mild adverse events.
Conclusions: PRP provides significant mid-term pain relief for chronic LBP. Apparent inconsistencies are driven by control selection and subjective/recall biases rather than biological unpredictability, highlighting the need for standardized future trials.